Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Han, J.-Y.
Right arrow Articles by Choi, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Han, J.-Y.
Right arrow Articles by Choi, B. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 30:435-439 (2000)
© 2000 Foundation for Promotion of Cancer Research

A Phase II Study of a Daily x4 Schedule of Vinorelbine Plus Cisplatin for Advanced Non-small Cell Lung Cancer

Ji-Youn Han1, Ki Won Kim1, Jung Ah Kim1, Jin Hyung Kang1, Jong-Youl Jin1, Young Seon Hong1, Suk Young Park1, Jung-Sup Song1, Jong Won Park1, Hoon-Kyo Kim1, Kyung Shik Lee1 and Byung Gil Choi2,+

Departments of 1Internal Medicine and 2Radiology, College of Medicine, Catholic University of Korea, Seoul, Korea

Background: Because dose intensity may be important as a determinant response to vinorelbine, we explored the possibility of increasing the dose intensity of vinorelbine on a daily x4 schedule.

Methods: Between February 1998 and March 1999, 31 patients with previously untreated advanced non-small cell lung cancer were enrolled. Vinorelbine 15 mg/m2 and cisplatin 20 mg/m2 were administered intravenously daily for 4 days and repeated every 21 days.

Results: A total 96 cycles were administered (median 3, range 1–6); 42% of vinorelbine and 39% of cisplatin injections were dose-reduced or delayed owing to toxicity. The actual dose intensity (DI) of vinorelbine was 17.7 mg/m2/week and that of cisplatin was 24 mg/m2/week. These figures represent 88 and 90% of the theoretical DI, respectively. The overall response rate was 40% (12/30, one CR). The main toxicity was myelosuppression: granulocytopenia WHO grade 3 and 4 in 24 patients (77%) and thrombocytopenia grade 3 in two patients (6%). The non-hematological toxicity was mild and tolerable. After a median follow-up of 7.5 months (range 3–21 months), the median progression-free survival and overall survival times were 5 months (95% CI, 3.8–6.2) and 8 months (95% CI, 4.5–11.5), respectively.

Conclusions: This regimen has a comparable therapeutic activity in patients with advanced lung cancers. However, despite supportive care there were excessive hematological toxicities. In view of increased toxicity and similar efficacy, this regimen is not indicated outside a clinical trial.

+ For reprints and all correspondence: Kyung Shik Lee, Department of Internal Medicine, College of Medicine, Catholic University of Korea, Kangnam St. Mary’s Hospital, 505 Banpo-dong, Seocho-gu, Seoul 137–040, Korea. E-mail: jymama@cmc.cuk.ac.kr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
J.-P. DELORD, C. PUOZZO, F. LEFRESNE, and R. BUGAT
Combination Chemotherapy of Vinorelbine and Cisplatin: A Phase I Pharmacokinetic Study in Patients with Metastatic Solid Tumors
Anticancer Res, February 1, 2009; 29(2): 553 - 560.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.